In summary, therefore, by shedding more light on the role of the ISR in mutant KRAS signaling and lung tumorigenesis, our work strongly suggests that innovative therapeutic approaches using ISR inhibitors may be valuable for the treatment of one of the deadliest forms of mutant KRAS-driven cancer. This evidence concerns the gene KRAS and cancer.